Clinical Trials Directory

Trials / Completed

CompletedNCT00897299

Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy

Identifying Genomic Predictors of Recurrence After Adjuvant Chemotherapy

Status
Completed
Phase
Study type
Observational
Enrollment
900 (estimated)
Sponsor
Eastern Cooperative Oncology Group · Network
Sex
Female
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict whether cancer will come back after treatment. PURPOSE: This laboratory study is identifying genes that may help predict recurrence in women with breast cancer treated with chemotherapy.

Detailed description

OBJECTIVES: * Assess the prognostic utility of the Oncotype DX™ 21 gene profile for risk of relapse in women with node positive or high-risk node negative breast cancer. * Identify individual genes whose RNA expression is associated with an increased risk of relapse in these patients. * Perform an exploratory analysis of individual genes whose RNA expression is associated with an increased risk of relapse differentially in patients previously treated with docetaxel. OUTLINE: This is a multicenter study. Tissue samples are examined for association of RNA expression and clinical factors (e.g., tumor size, nodal status, hormone receptor status, age, menopause status), as well as estrogen receptor, progesterone receptor, and HER-2/neu expression by immunohistochemistry and other studies. PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
GENETICmicroarray analysis
GENETICprotein expression analysis
OTHERimmunohistochemistry staining method
OTHERlaboratory biomarker analysis

Timeline

Start date
2005-10-07
Primary completion
2005-10-08
Completion
2005-10-08
First posted
2009-05-12
Last updated
2017-05-17

Source: ClinicalTrials.gov record NCT00897299. Inclusion in this directory is not an endorsement.